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doi:10.1016/j.ejvs.2011.07.019Abstract Objective: The aim of the study is to investigate the differential expression of
proteins in serum of abdominal aortic aneurysm (AAA) patients in relation to aneurysm size
(Dmax) and progression.
Methods: Two-dimensional differential in-gel electrophoresis (2D-DIGE) together with tandem
mass spectrometry (MS/MS) was used to analyse the serum proteome from patients with small
(Dmax 30e54 mm) AAA, either stable (increase Dmax <5 mm year
1; n Z 8) or progressive
(increase Dmax 5 mm year1; n Z 8), and large (Dmax 55 mm; n Z 8) AAA. The identified
proteins were quantitatively validated in a larger population (n Z 80).
Results: Several proteins were differentially expressed in serum of small stable, small progres-
sive and large AAA. Three validated proteins (immunoglobulin G (IgG), a1-antitrypsin (a1-AT)
and Factor XII activity) showed strong correlation with Dmax. Size combined with either Factor
XII activity or a1-antitrypsin had minimal effect on the prognostic value in predicting aneurysm
progression compared with size alone (area under the curve (AUC), 0.85; 95% confidence
interval (CI), 0.73e0.97; p < 0.001 and AUC, 0.85; 95% CI, 0.72e0.98; p < 0.001 vs. AUC,
0.83; 95% CI, 0.71e0.96; p < 0.001, respectively).
Conclusion: The present study indicates that both Factor XII and a1-antitrypsin are found in
increased amounts in the serum of patients with expanding AAA. However, combination of
either Factor XII or a1-antitrypsin with aneurysm diameter had little effect on prediction of
aneurysm progression versus diameter alone.
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564 B. Pulinx et al.Abdominal aortic aneurysm (AAA) is a degenerative disease
of the abdominal aorta leading to progressive dilatation, small stable, small progressive and large AAA. Differentialintraluminal thrombus (ILT) formation and rupture. Survival
associated with AAA rupture is extremely low, with rates
ranging from 10% to 15%, while elective surgery has an
overall survival rate of 95%. It is widely recognised that the
risk of rupture increases with increasing diameter, with the
threshold for elective repair at 55 mm diameter (Dmax).
However, a significant number of AAA 55 mm never
experience rupture,1 while small AAA can rupture unex-
pectedly.2 Early detection and elective AAA repair is, for
those at risk of rupture, a critical step to limit mortality
associated with aneurysm rupture.3 Better approaches are
needed for follow-up of patients with small asymptomatic
AAA. Most patients with small AAA are prospectively fol-
lowed by serial imaging until elective repair is indicated,37
although growth rate differs substantially between indi-
viduals.8 Besides identifying patients at risk for AAA
progression9,10 and rupture,11 new biomarkers may also
help to elucidate the molecular mechanisms behind this
disease and eventually generate treatments to reduce
progression rate.
Proteomics provides powerful opportunities to examine
protein expression patterns of tissues or body fluids.1215
Compared with conventional two-dimensional (2D) gel
electrophoresis, 2D differential in-gel electrophoresis (2D-
DIGE) enables quantitative comparison of protein expres-
sion and reduces the analytical variability through the use
of an internal standard.16
The aim of the present study was to detect differential
serum protein expression related to aneurysm size and
progression. To do so, we used 2D-DIGE together with
matrix-assisted laser desorption ionisation time-of-flight
tandem mass spectrometry (MALDI-TOF/TOF) to detectTable 1 Baseline demographics of patients with stable, progre
Stable AAA
(n Z 27)
P
(
Male sex 21 (77.8%)a 1
Age (years) Range 69.9  6.3c 7
(61e83) (
AAA diameter (mm) Range 36.6  4.2d 4
(31e43) (
Family history 6 (22.2%) 1
Hypertension 21 (77.8%) 1
Smoking historye
Never 1 (3.7%) 3
Quitted 18 (66.7%) 8
Current 8 (29.6%) 1
Coronary disease 12 (44.4%) 1
COPD 2 (7.4%) 2
PAD 13 (48.1%) 6
Chronic renal failure 3 (11.1%) 2
Statin use 18 (66.7%) 1
N.S. not significant different.
a Significantly different compared to large AAA: p Z 0.03.
b Significantly different compared to large AAA: p Z 0.01.
c Significantly different compared to large AAA: p Z 0.04.
d Significantly different compared to large AAA: p < 0.001.
e Smoking history is available for 26 patients with large AAA.and identify differentially expressed proteins between
expression of the identified proteins was quantitatively
validated using routine immunochemical techniques.
Materials and Methods
Sample collection
Between January 2006 and January 2009, blood samples
(e.g., serum, ethylene diamine tetraacetic acid (EDTA) and
citrate plasma) were obtained from patients with small
asymptomatic AAA, who were invited to participate in
a standardised 6-monthly follow-up study. Furthermore,
preoperative blood samples were obtained from patients
undergoing elective or emergency reconstruction of the
infrarenal abdominal aorta at the Department of Vascular
Surgery, Maastricht University Medical Centreþ (MUMCþ,
The Netherlands). The Medical Ethical Committee approved
the research protocol and all participants gave written
informed consent. The present study enrolled 48 consecu-
tive patients with small (Dmax 30e54 mm) asymptomatic
AAA, either stable (increase Dmax < 5 mm year
1; n Z 27)
or progressive (increase Dmax  5 mm year1; nZ 21), and
32 consecutive AAA patients undergoing elective open or
endovascular repair (Dmax  55 mm). Patients with symp-
tomatic, mycotic or ruptured AAA were excluded. Demo-
graphics of the study subjects at baseline were obtained by
interview and examination (Table 1). These included sex,
age, smoking habit (current smoker, ex-smoker since 1 year
or never smoked), hypertension (use of anti-hypertensive
drugs), family history, coronary disease (history of
unstable angina pectoris, myocardial infarction, coronaryssive and large AAA.
rogressive AAA
n Z 21)
Large AAA
(n Z 32)
ANOVA
p-value
5 (71.4%)b 31 (96.9%) 0.029
1.7  8.2 74.4  6.0 0.040
54e82) (63e87)
4.9  6.5d 72.1  10.1 <0.001
30e53) (55e92)
(4.8%) 7 (21.9%) N.S.
5 (71.4%) 19 (59.4%) N.S.
(14.3%) 3 (11.5%) N.S.
(38.1%) 14 (53.9%)
0 (47.6%) 9 (34.6%)
1 (52.4%) 16 (50.0%) N.S.
(9.5%) 5 (15.6%) N.S.
(28.6%) 5 (15.6%) 0.030
(9.5%) 3 (9.4%) N.S.
4 (66.7%) 17 (53.1%) N.S.
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nary angioplasty), chronic obstructive pulmonary disease
(COPD; based on the Global initiative for chronic Obstructive
Lung disease (GOLD) criteria),17 peripheral arterial disease
(PAD; ankle/brachial pressure index <0.9), chronic renal
failure (glomerular filtration rate <15 ml min1 $ 1.73 m2)
and statin use.
Blood was allowed to coagulate at room temperature for
30 min and centrifuged at 4000g for 15 min at 4 C. Exactly
1 h after blood collection, samples were stored in aliquots
at 80 C pending analysis. Maximal anterioreposterior
Dmax was measured by one observer, with intra-observer
variability of 2 mm (data not shown), using ultrasound for
follow-up patients and computed tomography angiography
before surgery.
Sample preparation
For 2D-DIGE, serum samples with no freezeethaw cycle
were selected from patients with either small stable
(n Z 8), small progressive (n Z 8) or large (n Z 8) AAA.
Samples from time point t were used to discover factors
prospectively predicting aneurysmal progression in 1 year.
Aneurysmal progression was calculated as the change in
Dmax from time point t to tþ12 months.
To improve the DIGE analysis, individual serum samples
were fractionated based on their biophysical properties
using the Expression Difference Mapping Kit (Bio-Rad
Laboratories Inc., Hercules, CA, USA). Six fractions were
obtained per patient; fractions pH3, pH4 and pH5 were
pooled together (denoted fraction A), and fractions pH7
and pH9 were mixed (denoted fraction B). The organic
fraction was discarded, as isoelectric focussing was carried
out on strips with a pH range of 3e10. The pH of the
fractions was adjusted to 8.5 by 50mM NaOH to obtain
optimal labelling conditions.
2-D DIGE
Fractions A and B were separately analysed, comparing
protein expression differences between the groups within
each fraction. Fractions from individual participants were
randomly labelled with Cy3 or Cy5, according to the
manufacturer’s instructions (GE Healthcare, Uppsala,
Sweden). Dye swapping was performed to control for
preferential labelling by one of the dyes. The labelling
reaction was quenched on ice in the dark for 10 min by
scavenging non-bound dye with 10 mM lysine (Sigma-
eAldrich, St. Louis, MO, USA). Three labelled samples, two
analytical and a Cy2-labelled internal standard were pooled
and an equal volume of 2  lysis buffer (7M urea, 2M
thiourea, 4% CHAPS buffer, 0.04% bromophenol blue, 2%
dithiothreitol (DTT), 2% IPG-buffer pH 3e10) was added.
Samples were focussed on an IPGphor using immobilised
DryStrip gels (3e10 pH range, non-linear, 18 cm), which
were passively pre-rehydrated for 6 h with DeStreak
Rehydration Solution supplemented with 0.5% IPG-buffer.
Strips were equilibrated for 15 min with gentle shaking in
equilibration solution (6M urea, 2% sodium dodecylsulphate
(SDS), 50mM Tris pH 8.8, 0.02% bromophenol blue, 30%
glycerol) supplemented with 1% DTT, followed by 2.5%iodoacetamide in fresh equilibration solution for an addi-
tional 15 min of incubation with gentle shaking. Second-
dimension sodium dodecylsulphateepolyacrylamide gel
electrophoresis (SDSePAGE) was carried out on poly-
acrylamide gels (12.5% T, 3% C) using Ettan DALTtwelve.
Gels were run at 20 C, 0.5 W gel1 for 1 h and 15 W gel1
until the bromophenol blue frontier reached the bottom of
the gel and subsequently scanned on the Ettan DIGE imager
using CyDye-specific excitation/emission wavelengths.
Gels were analysed using DeCyder 7.0 software (GE
Healthcare). Differentially expressed protein spots present
in >70% of the gels were selected for identification using
MS/MS.Protein identification and in-gel digestion
Preparative gels, loaded with 300 mg unlabelled protein,
were run using previous conditions. Gels were fixed for
30 min in 10% CH3OH and 7% CH3COOH followed by an
overnight incubation in Sypro Ruby (Bio-Rad). Thereafter,
gels were again fixed in 10% CH3OH and 7% CH3COOH for
45 min followed by a thorough rinse with milliQ. Protein
spots of interest were picked from the Sypro-stained gel
using the automated Ettan Spot Picker (GE Healthcare)
into 96-well plates and in-gel digestion was carried out on
the MassPREP digestion robot (Waters, Manchester, UK).
Gel plugs were destained twice in 100mM NH4HCO3, 50%
(v/v) CH3CN for 10 min, then dehydrated in 100% CH3CN for
5 min, after which supernatant was removed, and gel plugs
were allowed to air dry for 10 min. Cysteines were reduced
with 10mM DTT in 100mM NH4HCO3 for 30 min followed by
alkylation with 55mM iodoacetamide in 100mM NH4HCO3 for
20 min. Gel plugs were washed with 100mM NH4HCO3 and
subsequently dehydrated with 100% CH3CN. Trypsin sus-
pended in 50mM NH4HCO3 was added (12 ng ml
1) and
allowed to digest at 40 C for 5 h. Peptides were extracted
twice with 1% (v/v) formic acid, 2% (v/v) CH3CN.MS/MS and database analysis
Peptide solutions were mixed at a 1:1 ratio with 5 mg ml1
a-cyano-4-hydroxycinnamic acid (CHCA) matrix in 50%
CH3CN, 0.1% trifluoroacetic acid (TFA) and spotted in
duplo. Spots were allowed to air dry for homogeneous
crystallisation. Spectra were acquired in positive ion
reflectron mode on a 4800 MALDI-TOF/TOF analyser
(Applied Biosystems, Foster City, CA, USA). Tandem MS
fragmentation spectra were acquired for each sample,
averaging 500 laser shots per fragmentation spectrum on
each of the eight most abundant ions present in each
sample. The generated peak list was searched with the
MASCOT search engine by GPS Explorer v.3.9. Software
(Applied Biosystems) against the Swiss-Prot protein data-
base with taxonomy at Homo sapiens; trypsin and keratin
peaks were excluded. One mis-cleavage was tolerated;
carbamidomethylation was set as a fixed modification and
oxidation of methionine as an optional modification.
Protein charge was set at 1þ, mass tolerance for precursor
ion at 150 ppm and MS/MS tolerance at 0.2 Da. No
restrictions were made on protein mass. Identification was
566 B. Pulinx et al.considered confident when total ion and protein score
were above the 95% confidence interval (CI).
Laboratory validation measurements
Quantitative validation measurements were carried out
using native serum or citrate plasma from consecutive
patients with stable (n Z 27), progressive (n Z 21) and
large (n Z 32) AAA. Serum concentrations of alpha-1 anti-
trypsin (a1-AT) and immunoglobulin G (IgG) were analysed
on the BN ProSpec (Siemens Healthcare Diagnostics, The
Hague, The Netherlands). Analyses were performed at the
Department of Clinical Chemistry, MUMCþ with following
reference values: a1-AT (0.75e1.85 g l1) and IgG
(4.5e14.0 g l1). Citrate plasma Factor XII activity and D-
dimer concentrations were analysed on the Sysmex CA-7000
(Siemens Healthcare Diagnostics) at the Department of
Haematology, MUMCþ with following reference values:
60e140% and <500 ng ml1, respectively.
D-dimer was not found as one of the discriminating
proteins using DIGE, but was included as a ‘positive
control’ measurement testing the validity of our pop-
ulation, as recent literature has evidenced a clear rela-
tionship with AAA presence, diameter and
progression.1821
Statistical analysis
Data were analysed with Predictive Analytics Software
(PASW) Statistics 18.0 Software (IBM Corporation, Somers,
NY, USA). Categorical variables, expressed as percentages,
were compared using the Pearson chi-squared test. Analysis
of variance (ANOVA) was used to compare continuous
demographic variables, expressed as mean  standard
deviation, applying the Bonferroni correction for pair-wise
comparison. Associations between biomarker concentra-
tions and aneurysm diameter were calculated with linear
regression. Multivariate linear regression was used to
correct the associations for possible bias due age, sex and
PAD. One-way ANOVA with Bonferroni post hoc testing
(DeCyder 7.0 software, GE Healthcare) was used to detect
significant differences in protein abundances between the
three experimental groups.Figure 1 Proteome map of the differentially expressedResults
Identification of differentially expressed proteins
in serum from AAA patients
On average, approximately 700 spots were detected on
each gel. In total, 26 spots were differentially expressed
between patients with stable and large AAA; with two up-
regulated and nine down-regulated spots in fraction A and
three up-regulated and 12 down-regulated spots in fraction
B of patients with stable AAA. Fraction A as well as B
showed one up-regulated spot in patients with large AAA
compared with patients with progressive AAA. Only fraction
B revealed significant differential expression between
progressive and stable AAA, with eight spots up-regulated in
stable AAA.
All spot features of interest were trypsin digested and
submitted to MS/MS for identification. We were able to
identify seven spots representing five unique proteins that
were significantly differentially expressed between the
experimental groups (Fig. 1 and Table 2).
Validation of differentially expressed proteins in
serum from AAA patients
To confirm the 2D-DIGE differential protein expression,
quantitative validation of the results was carried out on
serum or citrate plasma using a larger sample set including
the samples analysed with DIGE (n Z 80). Although the
difference in Ig spot abundance between large and stable
AAA was minimal, significantly higher serum IgG concen-
trations were found in stable and progressive AAA
compared with large AAA (18.4  4.8 and 17.5  4.9 vs.
8.9  2.6 g l1, p < 0.001, Fig. 2A). Serum a1-AT concen-
trations were also increased in patients with stable and
progressive AAA relative to patients with large AAA
(1.62  0.25 and 1.62  0.37 vs. 1.16  0.25 g l1,
p < 0.001, Fig. 2B). Notably, serum IgG concentrations were
elevated above the upper reference limit in almost all small
AAA and were positively correlated (r Z 0.67; p < 0.001)
with serum a1-AT concentrations. Factor XII was down-
regulated in stable AAA, as indicated by the DIGEand identified proteins in fraction A and fraction B.
Table 2 Differentially expressed proteins in serum of stable, progressive and large AAA identified by MALDI-TOF/TOF after 2D-
DIGE analysis.
Swiss-Prot ID Name Total Ion
Score
(95% CI)a
Stable AAA Progressive
AAA
Large
AAA
ANOVA Stable
vs large
AAA
Stable vs
progressive
AAA
Progressive
vs large
AAA
Standardized abundance: mean  SD p-value p-value p-value p-value
Fraction A
P02768 Albumin 401 (100%) 1.27  0.36 1.98  0.80 2.54  0.62 0.009 0.007 e e
P01024 Complement
C3
215 (100%) 1.29  0.20 1.01  0.35 1.93  1.12 0.022 e e 0.020
P01009 a-1 antitrypsin 341 (100%) 1.89  0.75 1.14  0.28 1.03  0.51 0.026 0.025 e e
Fraction B
P00748 Factor XII 126 (100%) 0.09  0.04 0.36  0.36 0.99  0.59 <0.001 <0.001 e e
P01834 Ig k chain
C region
65 (100%) 1.06  0.10 0.98  0.15 0.88  0.08 0.043 0.032 e e
P01834 Ig k chain
C region
39 (99.95%) 1.06  0.17 0.87  0.10 0.87  0.12 0.025 0.042 0.044 e
P01834 Ig k chain
C region
309 (100%) 1.17  0.18 0.95  0.14 0.97  0.11 0.021 e 0.027 e
a This score describes the confidence of the identification and proteins with a confidence interval percentage above 95% were
considered confidently identified.
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lower in plasma of large AAA compared with stable and
progressive AAA (53.6  34.9 vs. 104.5  36.3 and
97.5  24.9%, p < 0.001, Fig. 2C). In almost all AAA
patients, plasma D-dimer concentrations were elevated
above the reference limit and were significantly different
between patients with stable, progressive and large AAA
(Fig. 2D).
Aneurysm size was significantly correlated with serum
IgG (r Z 0.65; p < 0.001), serum a1-AT (r Z 0.55;
p < 0.001), plasma D-dimer (r Z 0.62; p < 0.001)
concentrations and plasma Factor XII activity (r Z 0.48;
p < 0.001). Even after correcting for possible bias due to
differences in age, sex and PAD, the associations remained
significant (Table 3). As expected, aneurysm size shows
relatively good prognostic value in predicting aneurysm
progression (AUC, 0.83; 95% CI, 0.71e0.96; p < 0.001). The
prognostic value of the individual markers was not signifi-
cant, but aneurysm diameter combined with either Factor
XII activity or a1-AT, by regression, had minimal effect on
the prognostic value in predicting aneurysm progression
(AUC, 0.85; 95% CI, 0.73e0.97; p < 0.001 and AUC, 0.85;
95% CI, 0.72e0.98; p < 0.001, respectively; Fig. 3).
Although Ig spot abundance differs significantly between
stable and progressive AAA, making this a putative marker
for aneurysm progression, serum IgG concentration
combined with Dmax did not improve the ability to predict
aneurysm progression (AUC, 0.83; 95% CI, 0.71e0.96;
p < 0.001).Discussion
We detected differentially expressed proteins in the serum
from patients with stable, progressive and large AAA. These
differential proteins are involved in pathophysiological key
processes of AAA, such as inflammation (e.g., IgG),extracellular matrix (ECM) remodelling (e.g., a1-AT) or
coagulation and fibrinolysis (e.g., Factor XII).
In a recent review, members of the ‘Fighting Aneurysmal
Disease’ Consortium highlighted the role of ILT in AAA
pathogenesis.22 ILT is biologically active with at the luminal
interface active fibrinolysis and coagulation; markers of
these processes correlate with AAA size.18,19,23,24 D-dimer is
likely to be released as a breakdown product of continuous
thrombus remodelling.25 Furthermore, D-dimer is known to
stimulate synthesis and release of pro-inflammatory cyto-
kines from neutrophils and monocytes in vitro.26 Plasma D-
dimer concentrations show strong association with AAA
presence, diameter and progression.1821 This association
between D-dimer concentrations and AAA diameter was
confirmed in our patient population. We are the first to
correlate Factor XII with AAA size. Factor XII is involved in
the intrinsic coagulation cascade and is not required for
physiological coagulation in vivo as Factor XII deficiency
does not result in abnormal bleeding. It is hypothesised that
Factor XII plays a role in stabilising the fibrin clot. We found
an increased expression of Factor XII, combined with
a lower Factor XII activity in large compared with small
AAA. The fact that both Factor XII and its activity are highly
significantly related to aneurysm size suggests an excess
consumption of Factor XII. Further research regarding the
role of Factor XII in AAA is required to validate our findings.
Neutrophils predominate within the ILT and are a major
source of proteases associated with ECM degradation. In
this study, we detected and validated higher serum a1-AT
concentrations in patients with small compared with large
AAA. Alpha-1-AT is an acute-phase protein and serine
protease inhibitor, which inactivates enzymes, such as
elastase. Decreased amounts of a1-AT in serum facilitate
proteolytic ECM degradation, weakening the vascular wall,
resulting in dilatation and making it more prone to rupture.
In agreement with our study, Schachner et al. demon-
strated that a1-AT concentrations are reduced in the
Figure 2 Validation of differential (A) serum IgG (B) serum a-1 antitrypsin (C) plasma Factor XII activity, and (D) plasma D-dimer
expression in eighty patients with abdominal aortic aneurysm. Dashed lines show the reference values, as established at our
hospital. Significant difference compared to large AAA is indicated by )p < 0.001 or #p Z 0.002.
568 B. Pulinx et al.vascular wall of ascending aortic dissections compared with
healthy aortas.27 Furthermore, Lindholt et al. and Vega de
Ce´niga et al. both showed a positive relation between AAA
progression and serum a1-AT concentrations, but were not
able to demonstrate any relation with AAA diameter.28,29 In
contrast to a1-AT, IgG measurements in addition to aneu-
rysm size did not improve the ability to predict aneurysm
progression. Correlation between serum a1-AT and IgG
concentrations suggests that a1-AT up-regulation in small
AAA is associated with inflammation and to a lesser extent
with ECM degradation. Inflammation is a key process in AAA
formation, as demonstrated by extensive inflammatory cell
infiltration,30 but it remains unclear whether this inflam-
mation is causal or simply a reaction to ECM degradation.
Here, we showed the increased expression of serum IgG in
small AAA. Based on positive associations between AAA
size and cytokines as well as other inflammatoryTable 3 Linear regression assessing the individual relation
between biomarker and Dmax.
B (SE) p-value Goodness
of fit
a1-antitrypsin 21.29 (4.80) <0.001 0.381
IgG 1.66 (0.25) <0.001 0.505
D-dimer 0.004 (0.001) <0.001 0.482
Factor XII activity 0.17 (0.04) <0.001 0.336
Corrected for possible bias due to age, sex and PAD.markers,29,3133 higher serum IgG concentrations would
be expected in large AAA. This discrepancy could be
explained by the hypothesis that inflammation has dimin-
ished in large AAA and progression is more likely due to
haemodynamic factors. This hypothesis is partly supported
by a recent publication of Parry and colleagues, in which
they observed elevated C-reactive protein (CRP) and
fibrinogen levels in men with small AAA reflecting a pro-
inflammatory state.21
However, some limitations should also be addressed.
This proteomic technique has a low resolution for alkaline,
less abundant and high-molecular-weight proteins, and
a number of differential proteins could not be identified
with the presently available techniques. The tremendous
dynamic range of protein concentrations in serum limits
biomarker discovery using 2D-DIGE and depleting the most
abundant proteins has received considerable attention.
However, the removal process must be close to 100% effi-
ciency to be interesting and less abundant proteins may
also be eliminated during the depletion process, due to
carrier function of albumin or a specific removal, resulting
in loss of reliable information and potential discrepancies
between samples. Furthermore, investigating the correla-
tion of biomarker concentrations, especially Factor XII, and
ILT volume would be valuable. Unfortunately, data on ILT
volume are only available for a limited amount of patients
with small AAA, as aneurysm size was assessed using
ultrasound in the majority of patients.
In summary, we report a proteomic study on serum
samples of AAA patients. The differentially expressed
Figure 3 Prediction of aneurysm progression by the indi-
vidual parameters (dotted line) and parameters combined with
aneurysm size (full line). IgG (blue), a-1 antitrypsin (red),
Factor XII (green) and aneurysm size (black).
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several key features of AAA pathophysiology. Incorporating
either Factor XII activity or a1-AT measurements together
with aneurysm diameter did not have a marked effect on
the prediction of aneurysm progression. Further research,
with larger sample sizes, is necessary to investigate
whether these or other serum markers of AAA reflect
causative factors for aneurysm formation and progression,
or are merely secondary effects of aneurysm presence.Conflict of Interest
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